ストックスクリーナーアプリを入手
8.18
1.61%
0.13
前日終値:
$8.05
開ける：
$8.15
24時間の取引高:
280.64K
Relative Volume:
1.46
時価総額：
$414.30M
収益：
-
当期純損益:
$-29.42M
株価収益率:
-9.4164
EPS:
-0.8687
ネットキャッシュフロー:
$-25.01M
1週間 パフォーマンス:
+0.74%
1か月 パフォーマンス:
-4.55%
6か月 パフォーマンス:
+61.98%
1年 パフォーマンス:
+90.68%
1日の値動き範囲:
$7.97
$8.24
1週間の範囲:
$7.97
$8.79
52週間の値動き範囲:
$2.6801
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Compare EPRX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
8.18 | 407.72M | 0 | -29.42M | -25.01M | -0.8687 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.13 | 122.71B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
770.79 | 82.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
771.53 | 50.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.24 | 43.42B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
322.37 | 38.98B | 4.98B | 69.60M | 525.67M | 0.5198 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2025-06-16 | 開始されました | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | 開始されました | Craig Hallum | Buy |
| 2024-11-14 | 開始されました | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc (EPRX) 最新ニュース
(EPRX.WT.A) Trading Report (EPRX.WT.A:CA) - Stock Traders Daily
(EPRX) Proactive Strategies (EPRX:CA) - Stock Traders Daily
Bloom Burton initiates Eupraxia stock with buy rating on EoE drug - Investing.com Nigeria
Bloom Burton initiates Eupraxia stock with buy rating on EoE drug By Investing.com - Investing.com Australia
(EPRX.WT.A) Technical Pivots with Risk Controls - Stock Traders Daily
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Eupraxia Pharmaceuticals closes $63.2M public offering - Investing.com India
Eupraxia Pharmaceuticals closes $63.2M public offering By Investing.com - Investing.com Canada
Eupraxia Pharmaceuticals stock gains after $63M offering - Investing.com Nigeria
Eupraxia Pharmaceuticals stock gains after $63M offering By Investing.com - Investing.com UK
Eupraxia Pharmaceuticals Raises US$63.2 Million to Advance GI Pipeline and Commercial Readiness - TipRanks
Eupraxia Pharmaceuticals Closes $63.2 Million Offering - marketscreener.com
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option - The Manila Times
Eupraxia Pharmaceuticals Announces Closing of US$63.2 - GlobeNewswire
Long Term Trading Analysis for (EPRX.WT.A) - Stock Traders Daily
Eupraxia Pharmaceuticals Launches Cross-Border Equity and Warrant Offering Under New Underwriting Pact - TipRanks
Eupraxia Pharmaceuticals stock falls after pricing $55 million offering By Investing.com - Investing.com Canada
Eupraxia Pharmaceuticals Prices $55 Million Public Offering - marketscreener.com
Eupraxia Pharmaceuticals prices $55 million public offering - Investing.com Nigeria
Eupraxia Pharmaceuticals stock falls after pricing $55 million offering - Investing.com India
Eupraxia Pharma Prices $55 Mln Offering Of Shares And Warrants; Stock Down - Nasdaq
US Stocks Recap: Will Eupraxia Pharmaceuticals Inc stock hit new highs in YEAR2025 Geopolitical Influence & Comprehensive Market Scan Reports - baoquankhu1.vn
Eupraxia Prices $55 Mln Offering To Advance Diffusphere Pipeline - Nasdaq
Eupraxia Pharmaceuticals announces pricing of US $55 million public offering of common shares and pre-funded warrants - marketscreener.com
Eupraxia Raises US$55 Million to Accelerate EP-104GI and GI Pipeline - TipRanks
Eupraxia Pharmaceuticals Announces Pricing Of US $55 Million Public Offering Of Common Shares And Pre-Funded Warrants - TradingView
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million - GlobeNewswire
Biotech raises $55M to advance new Eosinophilic Esophagitis drug - Stock Titan
Eupraxia Pharmaceuticals Announces Proposed Public Offering - Investing News Network
Eupraxia Pharmaceuticals Plans Public Offering to Fund GI Drug Pipeline - TipRanks
(EPRX.WT.A) Stock Market Analysis - Stock Traders Daily
Will Eupraxia Pharmaceuticals Inc. stock maintain momentum in 2025Earnings Risk Report & Daily Profit Focused Stock Screening - mfd.ru
(EPRX) Daily Stock Insights (EPRX:CA) - Stock Traders Daily
(EPRX.WT.A) Equity Trading Insights - Stock Traders Daily
Will Eupraxia Pharmaceuticals Inc. benefit from rising consumer demandJuly 2025 Price Swings & Low Risk High Reward Trade Ideas - mfd.ru
What’s the beta of Eupraxia Pharmaceuticals Inc. stockQuarterly Earnings Report & Risk Managed Trade Strategies - mfd.ru
Rate Hike: What are Eupraxia Pharmaceuticals Incs recent SEC filings showingWeekly Profit Report & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Is Eupraxia Pharmaceuticals Inc. a good stock for dollar cost averaging2025 Winners & Losers & Free Technical Pattern Based Buy Signals - mfd.ru
(EPRX) Stock Trading Blueprint (EPRX:CA) - Stock Traders Daily
Can Eupraxia Pharmaceuticals Inc. stock deliver sustainable ROEQuarterly Trade Report & Daily Profit Focused Stock Screening - mfd.ru
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Buy" by Brokerages - MarketBeat
(EPRX.WT.A) Strategic Investment Guide - Stock Traders Daily
Risk Off: Is Eupraxia Pharmaceuticals Inc affected by consumer sentimentWeekly Earnings Recap & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Valuation Update: Can Eupraxia Pharmaceuticals Inc beat the S P 500July 2025 Reactions & Community Consensus Trade Signals - baoquankhu1.vn
Is HBOS plc Preferred Security forming a double bottomWeekly Earnings Recap & Real-Time Price Movement Reports - baoquankhu1.vn
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 3.8%What's Next? - MarketBeat
(EPRX.WT.A) Advanced Trading Insights - Stock Traders Daily
Eupraxia Pharmaceuticals (TSX:EPRX) Trades With S&P/TSX Index - Kalkine Media
Here's Why We're Not At All Concerned With Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation - Yahoo Finance
Eupraxia Pharmaceuticals Inc (EPRX) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
0.59%
大文字化:
|
ボリューム (24 時間):